BCL2 and plasma cell myeloma: Bone marrow mesenchymal stem cells derived exosomal miR-483 increased multiple myeloma’s malignant progression by inhibiting TIMP2 expression [76], and the inhibition of miR483 increased expression of p21 and downregulated the expression of c-Myc and Bcl-2 [76].